PUBLISHER: DelveInsight | PRODUCT CODE: 1226672
PUBLISHER: DelveInsight | PRODUCT CODE: 1226672
DelveInsight's "Respiratory syncytial virus (RSV) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the RSV, historical and forecasted epidemiology as well as the RSV market trends in the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.
The RSV market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted RSV market size from 2019 to 2032, segmented by seven major markets. The report also covers current RSV treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Study period: 2019-2032.
The DelveInsight's "Respiratory syncytial virus (RSV) market" report gives a thorough understanding of RSV by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
RSV is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human RSV, bovine RSV, and murine pneumonia virus. Two major antigenic subtypes of human RSV (A and B) are determined mainly by antigenic drift and duplications in RSV-G sequences but accompanied by genome-wide sequence divergence, including within RSV-F. Signs and symptoms of RSV infection most commonly appears about 4-6 days after exposure to the virus. RSV usually causes mild cold-like signs and symptoms in adults and older children. Signs and symptoms of severe RSV infection in infants include rapid breathing, cough, poor feeding, irritability, and unusual tiredness.
Testing for RSV is often not needed. If it is required, several types of laboratory tests are used for diagnosis. The most commonly used is the rapid diagnostic test. This test looks for RSV antigens in nasal secretions. If the rapid test is negative, the doctor may order a virus culture of the secretions. The doctor may also choose a more sensitive test that uses genetic technology to detect the virus in the blood. Laboratory tests for RSV include rapid antigen detection tests (RADTs), direct fluorescent antibody (DFA), polymerase chain reaction (PCR), and viral cultures. Other tests include a blood test, chest x-rays, and pulse oximetry.
Supportive care is the mainstay of treatment for RSV bronchiolitis. Most infants can be managed at home, but those who are ill-appearing, dehydrated, have poor feeding or apnea, develop respiratory distress or require supplemental oxygen should be considered for hospitalization. The typical length of stay in the hospital ranges 3-7 days. Supportive care includes hydration (i.e., oral or intravenous), clearing nasal obstruction with saline nose drops, nasal bulb suction or deep suctioning in the hospital, and nutrition for the patient. Bronchodilators, corticosteroids, antibiotics, and others are also used to treat RSV.
The Respiratory syncytial virus (RSV) epidemiology section provides insights into the historical and current RSV patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Respiratory syncytial virus (RSV) epidemiology segmented as Total Incident Cases of RSV, Age-specific Incident Cases of RSV, Severity-specific Incident Cases of RSV in children, Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in adults and Visit-specific Incident Cases of RSV in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) the United Kingdom, and Japan from 2019 to 2032.
This section provides a glimpse of the Respiratory syncytial virus (RSV) epidemiology in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.
The drug chapter segment of the Respiratory syncytial virus (RSV) report encloses a detailed analysis of RSV-marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Respiratory syncytial virus (RSV) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Palivizumab is a humanized monoclonal antibody (IgG1?) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. In June 1998, SYNAGIS was approved to prevent serious lower respiratory tract disease caused by RSV in pediatric patients in the US.
Note: Detailed current therapies assessment will be provided in the full report of Respiratory syncytial virus (RSV).
Pfizer's investigational RSV vaccine candidate, RSVpreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that RSV uses to attack human cells. In March 2022, Pfizer announced that its RSV vaccine candidate, PF-06928316 or RSVpreF, received BTD from the US FDA to prevent lower respiratory tract disease caused by RSV in individuals 60 years or older.
GSK3844766A contains a recombinant subunit pre-fusion RSV antigen combined with GSK's proprietary AS01 adjuvant, which is also used in the company's shingles vaccine. The drug has accepted regulatory submissions in Europe and Japan for older adults aged 60+. The Regulatory decision in the US is expected in the first half of 2023. US FDA has set a Prescription Drug User Fee Act action date of May 2023.
The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 RSV vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response. In August 2021, Moderna received the FDA's FTD for the RSV vaccine (mRNA-1345) in adults older than 60.
"BEYFORTUS (nirsevimab), targeting the age segment of 0-1 years, bears an impressive efficacy, has a single dose schedule, was granted marketing authorization in the European Union in 2022, and is expected to launch this year in the US. The drug is expected to capture a significant market share considering half of the infants will receive the vaccine for RSV by its peak year. In the 'older adult' age segment, GSK's vaccine RSVPreF3 outperforms Pfizer's vaccine. With the high vaccine efficacy demonstrated in this pivotal trial, GSK's vaccine candidate has the potential to help reduce the significant global burden of RSV-associated disease in older adults, including those at the greatest risk of severe outcomes due to their age or underlying comorbidities. It seems that Moderna's recent results may spoil the limelight from both GSK and Pfizer. On January 2023, Moderna announced results from the Phase III pivotal efficacy trial of mRNA-1345; the results were competitive with GSK and Pfizer's drug giving them tough competition."
Note: Detailed emerging therapies assessment will be provided in the full report of Respiratory syncytial virus (RSV).
While understanding Respiratory syncytial virus (RSV) pathogenesis and viral biology has increased over time, prevention of the virus is still lacking, often with severe disease burdens. Treatment for RSV infection is currently limited to supportive care and prophylactic antibody use. It may include hydration, supplemental oxygen, suctioning of airways, and mechanical ventilation when needed.
The FDA approves only two RSV antiviral drugs for treating or preventing serious respiratory tract infections caused by RSV: aerosolized ribavirin for treatment and palivizumab (SYNAGIS) for prophylaxis. Currently, multiple types of RSV vaccines are being pursued, specifically targeting populations of pregnant women, infants, and the elderly.
Based on the secondary sources and KOL insights for a prescription pattern of palivizumab in real-world settings, the usage of palivizumab in the US was around 20-25% whereas, in Europe and Japan, the utilization of palivizumab was comparatively less.
There is an unmet need for clinically effective, safe, cost-effective prevention and treatment options, including antiviral treatments, vaccines, and extended half-life mAbs. Challenges that must be encountered while generating safe and effective RSV vaccines or monoclonals include stringent safety measures in targeted pediatric and maternal populations. The development of novel RSV vaccines will hopefully help reduce the global burden caused by RSV. Until new interventions become available, optimizing the use of palivizumab in high-risk infants and children is important.
This section provides the total Respiratory syncytial virus (RSV) market size and market size by therapies in the United States.
This section provides the total Respiratory syncytial virus (RSV) market size and market size by therapies in EU4 and the UK.
This section provides the total Respiratory syncytial virus (RSV) market size and market size by therapies in Japan.
This section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory syncytial virus (RSV) market or expected to get launched in the market during the study period 2019-2032. The analysis covers RSV market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II and III. It also analyzes RSV key players in developing targeted therapeutics.
The report covers collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging RSV therapies.
Approaching reimbursement proactively can positively impact both during the late stages of product development and after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the Respiratory syncytial virus (RSV) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or RSV market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Respiratory syncytial virus (RSV) market using various competitive intelligence tools like SWOT analysis. The inclusion of the analysis entirely depends upon the data availability.